Our Technologies

Localized Steroid-Releasing Technology

Intersect ENT’s core technology is its bioabsorbable drug release platform. The current portfolio of sinus implants is designed to provide mechanical support and localized drug delivery.

Localized Steroid-Releasing Technology

Intersect ENT’s core technology is its bioabsorbable drug release platform. The current portfolio of sinus implants is designed to provide mechanical support and localized drug delivery.

PROPEL family of products

FDA Approved

propel logo

Used to maintain the sinus opening after ethmoid sinus surgery

propel mini logo

Used to maintain the sinus opening after ethmoid or frontal sinus surgery

PROPEL Contour logo

Used to maintain the sinus opening after frontal or maxillary sinus surgery

The PROPEL sinus implants are intended for use after sinus surgery to maintain patency and to locally deliver steroid to the sinus mucosa: PROPEL for use in the ethmoid sinus, PROPEL Mini for use in the ethmoid sinus and frontal sinus opening, and PROPEL Contour for use in the frontal and maxillary sinus ostia. The implants are intended for use in patients ≥18 years of age. Contraindications include patients with intolerance to mometasone furoate (MF) or a hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implants in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For complete prescribing information see IFU at www.IntersectENT.com. Rx only.